Table 3.
The efficacy of immunosuppressive therapy.
| At the initiation of immunosuppressive therapy | At final visit | |
|---|---|---|
| Median ARR of ON (first-third quartile) | 0.33 (0–0.45) | 0 (0–0) |
| Median ARR of ON, myelitis, and encephalitis episode (first-third quartile) | 0.37 (0.17–0.55) | 0 (0–0.13) |
| Mean PSL dosage (mg/day) (SD) | 17.8 (7.1) | 6.2 (2.4) |
| Mean logMAR BCVA (SD) | ||
| Dominant eye | −0.1 (0.2) | −0.1 (0.2) |
| Nondominant eye | 0.9 (1.0) | 0.9 (1.0) |
| Mean GCL + thickness (μm) (SD) | ||
| Dominant eye | 59.5 (12.5) | 57.5 (10.5) |
| Nondominant eye | 49.8 (15.3) | 45.4 (14.5) |
| Mean cpRNFL thickness (μm) (SD) | ||
| Dominant eye | 71.2 (21.0) | 74.4 (18.1) |
| Nondominant eye | 59.9 (22.1) | 58.0 (13.4) |
ARR: annualized relapse rate, ON: optic neuritis, PSL: prednisolone, SD: standard deviation, BCVA: best-corrected visual acuity, GCL: ganglion cell layer, cpRNFL: circumpapillary retinal nerve fiber layer.